• Je něco špatně v tomto záznamu ?

Structure-Based Identification of Naphthoquinones and Derivatives as Novel Inhibitors of Main Protease Mpro and Papain-like Protease PLpro of SARS-CoV-2

LH. Santos, T. Kronenberger, RG. Almeida, EB. Silva, REO. Rocha, JC. Oliveira, LV. Barreto, D. Skinner, P. Fajtová, MA. Giardini, B. Woodworth, C. Bardine, AL. Lourenço, CS. Craik, A. Poso, LM. Podust, JH. McKerrow, JL. Siqueira-Neto, AJ....

. 2022 ; 62 (24) : 6553-6573. [pub] 20220812

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem, Research Support, N.I.H., Extramural

Perzistentní odkaz   https://www.medvik.cz/link/bmc22032103

Grantová podpora
P50 AI150476 NIAID NIH HHS - United States
T32 GM145460 NIGMS NIH HHS - United States
U19 AI171110 NIAID NIH HHS - United States

The worldwide COVID-19 pandemic caused by the coronavirus SARS-CoV-2 urgently demands novel direct antiviral treatments. The main protease (Mpro) and papain-like protease (PLpro) are attractive drug targets among coronaviruses due to their essential role in processing the polyproteins translated from the viral RNA. In this study, we virtually screened 688 naphthoquinoidal compounds and derivatives against Mpro of SARS-CoV-2. Twenty-four derivatives were selected and evaluated in biochemical assays against Mpro using a novel fluorogenic substrate. In parallel, these compounds were also assayed with SARS-CoV-2 PLpro. Four compounds inhibited Mpro with half-maximal inhibitory concentration (IC50) values between 0.41 μM and 9.0 μM. In addition, three compounds inhibited PLpro with IC50 ranging from 1.9 μM to 3.3 μM. To verify the specificity of Mpro and PLpro inhibitors, our experiments included an assessment of common causes of false positives such as aggregation, high compound fluorescence, and inhibition by enzyme oxidation. Altogether, we confirmed novel classes of specific Mpro and PLpro inhibitors. Molecular dynamics simulations suggest stable binding modes for Mpro inhibitors with frequent interactions with residues in the S1 and S2 pockets of the active site. For two PLpro inhibitors, interactions occur in the S3 and S4 pockets. In summary, our structure-based computational and biochemical approach identified novel naphthoquinonal scaffolds that can be further explored as SARS-CoV-2 antivirals.

000      
00000naa a2200000 a 4500
001      
bmc22032103
003      
CZ-PrNML
005      
20230131151238.0
007      
ta
008      
230120s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acs.jcim.2c00693 $2 doi
035    __
$a (PubMed)35960688
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Santos, Lucianna H $u Department of Biochemistry and Immunology, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais 31270-901, Brazil
245    10
$a Structure-Based Identification of Naphthoquinones and Derivatives as Novel Inhibitors of Main Protease Mpro and Papain-like Protease PLpro of SARS-CoV-2 / $c LH. Santos, T. Kronenberger, RG. Almeida, EB. Silva, REO. Rocha, JC. Oliveira, LV. Barreto, D. Skinner, P. Fajtová, MA. Giardini, B. Woodworth, C. Bardine, AL. Lourenço, CS. Craik, A. Poso, LM. Podust, JH. McKerrow, JL. Siqueira-Neto, AJ. O'Donoghue, EN. da Silva Júnior, RS. Ferreira
520    9_
$a The worldwide COVID-19 pandemic caused by the coronavirus SARS-CoV-2 urgently demands novel direct antiviral treatments. The main protease (Mpro) and papain-like protease (PLpro) are attractive drug targets among coronaviruses due to their essential role in processing the polyproteins translated from the viral RNA. In this study, we virtually screened 688 naphthoquinoidal compounds and derivatives against Mpro of SARS-CoV-2. Twenty-four derivatives were selected and evaluated in biochemical assays against Mpro using a novel fluorogenic substrate. In parallel, these compounds were also assayed with SARS-CoV-2 PLpro. Four compounds inhibited Mpro with half-maximal inhibitory concentration (IC50) values between 0.41 μM and 9.0 μM. In addition, three compounds inhibited PLpro with IC50 ranging from 1.9 μM to 3.3 μM. To verify the specificity of Mpro and PLpro inhibitors, our experiments included an assessment of common causes of false positives such as aggregation, high compound fluorescence, and inhibition by enzyme oxidation. Altogether, we confirmed novel classes of specific Mpro and PLpro inhibitors. Molecular dynamics simulations suggest stable binding modes for Mpro inhibitors with frequent interactions with residues in the S1 and S2 pockets of the active site. For two PLpro inhibitors, interactions occur in the S3 and S4 pockets. In summary, our structure-based computational and biochemical approach identified novel naphthoquinonal scaffolds that can be further explored as SARS-CoV-2 antivirals.
650    _2
$a lidé $7 D006801
650    12
$a antivirové látky $x farmakologie $x chemie $7 D000998
650    _2
$a COVID-19 $7 D000086382
650    _2
$a simulace molekulového dockingu $7 D062105
650    12
$a naftochinony $x chemie $x farmakologie $7 D009285
650    _2
$a papain $7 D010206
650    12
$a inhibitory proteas $x farmakologie $x chemie $7 D011480
650    12
$a SARS-CoV-2 $x účinky léků $x enzymologie $7 D000086402
650    12
$a koronavirové proteasy 3C $x antagonisté a inhibitory $7 D000086782
650    12
$a koronavirové proteasy podobné papainu $x antagonisté a inhibitory $7 D000086882
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
700    1_
$a Kronenberger, Thales $u Department of Oncology and Pneumonology, Internal Medicine VIII, University Hospital Tübingen, Otfried-Müller-Straße 10, DE72076 Tübingen, Germany $u School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland $u Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry and Tübingen Center for Academic Drug Discovery (TüCAD2), Eberhard Karls University Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany $1 https://orcid.org/0000000169337590
700    1_
$a Almeida, Renata G $u Institute of Exact Sciences, Department of Chemistry, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais 31270-901, Brazil
700    1_
$a Silva, Elany B $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093-0657, United States $1 https://orcid.org/0000000219263500
700    1_
$a Rocha, Rafael E O $u Department of Biochemistry and Immunology, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais 31270-901, Brazil
700    1_
$a Oliveira, Joyce C $u Institute of Exact Sciences, Department of Chemistry, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais 31270-901, Brazil
700    1_
$a Barreto, Luiza V $u Department of Biochemistry and Immunology, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais 31270-901, Brazil
700    1_
$a Skinner, Danielle $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093-0657, United States
700    1_
$a Fajtová, Pavla $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093-0657, United States $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 16610 Prague, Czech Republic
700    1_
$a Giardini, Miriam A $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093-0657, United States $1 https://orcid.org/0000000265102409
700    1_
$a Woodworth, Brendon $u Department of Medicine, Division of Infectious Diseases, University of California San Diego, La Jolla, California 92093, United States
700    1_
$a Bardine, Conner $u Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California 94143, United States $1 https://orcid.org/0000000348892944
700    1_
$a Lourenço, André L $u Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California 94143, United States
700    1_
$a Craik, Charles S $u Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California 94143, United States $1 https://orcid.org/0000000177049185
700    1_
$a Poso, Antti $u Department of Oncology and Pneumonology, Internal Medicine VIII, University Hospital Tübingen, Otfried-Müller-Straße 10, DE72076 Tübingen, Germany $u School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland $1 https://orcid.org/0000000341964204
700    1_
$a Podust, Larissa M $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093-0657, United States $1 https://orcid.org/0000000285378760
700    1_
$a McKerrow, James H $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093-0657, United States $1 https://orcid.org/0000000251524627
700    1_
$a Siqueira-Neto, Jair L $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093-0657, United States $1 https://orcid.org/0000000195748174
700    1_
$a O'Donoghue, Anthony J $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093-0657, United States $1 https://orcid.org/0000000156950409
700    1_
$a da Silva Júnior, Eufrânio N $u Institute of Exact Sciences, Department of Chemistry, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais 31270-901, Brazil
700    1_
$a Ferreira, Rafaela S $u Department of Biochemistry and Immunology, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais 31270-901, Brazil $1 https://orcid.org/0000000333240601
773    0_
$w MED00008945 $t Journal of chemical information and modeling $x 1549-960X $g Roč. 62, č. 24 (2022), s. 6553-6573
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35960688 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151234 $b ABA008
999    __
$a ok $b bmc $g 1891091 $s 1183438
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 62 $c 24 $d 6553-6573 $e 20220812 $i 1549-960X $m Journal of chemical information and modeling $n J Chem Inf Model $x MED00008945
GRA    __
$a P50 AI150476 $p NIAID NIH HHS $2 United States
GRA    __
$a T32 GM145460 $p NIGMS NIH HHS $2 United States
GRA    __
$a U19 AI171110 $p NIAID NIH HHS $2 United States
LZP    __
$a Pubmed-20230120

Najít záznam

Citační ukazatele

Nahrávání dat...

Možnosti archivace

Nahrávání dat...